Health Canada approved Idorsia’s JERAYGO (aprocitentan) for adults with resistant hypertension on at least three antihypertensives, starting at 12.5 mg once daily and titratable to 25 mg. Phase 3 PRECISION data in 730 patients showed rapid, durable double-digit systolic blood pressure reductions at Week 4 sustained through Week 40, supporting potential market uptake.